Genexine
Company Details
Status: Public
Employees: 101-250
Location:
Bundang-Gu, Seognam-si, Gyeonggi-do, South Korea
Type:
sample
sample
Technology:
sample
sample
sample
About: Genexine has robust R&D pipelines in clinical and pre-clinical stages based on long-acting Fc-fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) co-developed with Handok for both adult and pediatric GHD, currently finished multinational Phase 2 trials and preparing for global Phase 3 trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase 2 in Europe and Korea for Cervical Intraepithelial Neoplasia II/III. Combined with Merck’s Keytruda, GX-188E recently is in Phase 1b/2a trial for cervical cancer. HyLeukin-7 (Immuno-oncology agent, IL-7-hyFc) has finished Phase 1 trial in Korea and received IND approval from US FDA. Currently, Genexine is running more than 7 clinical trials globally. In addition to collaboration with Merck, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Simcere Pharma, Kalbe Pharma, and Korean big Pharma companies such as Handok, Green Cross and Yuhan.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Genexine | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.